



# Stereocontrolled formation of cephams from 1,3-*O*-ethylidene-L-erythritol<sup>†</sup>

Katarzyna Borsuk,<sup>a</sup> Kinga Suwińska<sup>b</sup> and Marek Chmielewski<sup>a,\*</sup>

<sup>a</sup>*Institute of Organic Chemistry of the Polish Academy of Sciences, 01-224 Warsaw, Poland*

<sup>b</sup>*Institute of Physical Chemistry of the Polish Academy of Sciences, 01-224 Warsaw, Poland*

Received 15 March 2001; accepted 5 April 2001


**Abstract**—[2+2]Cycloaddition of chlorosulfonyl isocyanate to (*Z*)-1,3-*O*-ethylidene-2-*O*-propenyl-4-*O*-trityl-L-erythritol proceeds with excellent stereoselectivity to afford the corresponding (*R*)-4'-alkoxy-azetidin-2-one which can be transformed into 5-oxacepham by intramolecular alkylation of the  $\beta$ -lactam nitrogen atom. Cepham having the alternative (*S*) configuration at the bridgehead carbon atom can be achieved by another methodology based on alkylation of the nitrogen atom in 4-vinyloxy-azetidin-2-one by the suitably protected 1,3-ethylidene-L-erythritol followed by intramolecular displacement of the vinyloxy group. © 2001 Elsevier Science Ltd. All rights reserved.

Recently we have shown that [2+2]cycloaddition of chlorosulfonyl isocyanate (CSI) to 3-*O*- and 5-*O*-vinyl ethers of 1,2-*O*-isopropylidene-D-glycofuranose proceeds in many cases with excellent stereoselectivity and allows control of the configuration at C-(4) of the 4-alkoxy-azetidin-2-one.<sup>1–3</sup> The cycloadducts offer an entry to 5-oxacephams and clavams via suitable transformation of the sugar auxiliary.<sup>4,5</sup> Due to the specific multifunctional character of the 1,2-*O*-isopropylidene-D-glycofuranose residue, previously presented syntheses<sup>4,5</sup> are of limited practical value.

Herein, we demonstrate that the stereochemical [2+2]-cycloaddition model proposed by us recently<sup>6</sup> has a general applicability and that alternative strategies for the formation of 5-dethia-5-oxa-cephams<sup>7</sup> offer full control of the configuration at the bridgehead carbon atom of the antibiotic, C-(6).

For these model studies we selected 1,3-*O*-ethylidene-L-erythritol **1**, which is readily synthesized from D-glucose.<sup>8</sup> The terminal hydroxymethyl group in **1** was protected as a trityl<sup>9</sup> or *tert*-butyldimethylsilyl (TBS)<sup>10</sup> ether and the secondary hydroxyl was protected as its allyl ether. The allyl substituent in compound **3** was then transformed into the corresponding (*Z*)-propenyl ether **6**,<sup>11</sup> by the standard potassium *tert*-butoxide isomerization.<sup>12</sup> In the case of **5**, isomerization of the allyl ether caused concomitant deprotection of the silyl ether, yielding **7**. The hydroxyl group in **7** was mesylated or tosylated under standard conditions to afford the corresponding sulfonates **8** and **9**.


It has been shown that both vinyl and (*Z*)-propenyl ethers display the same direction of asymmetric induction in [2+2]cycloadditions with CSI.<sup>12</sup> Since the formation of vinyl ethers requires acid catalysis, which could



\* Corresponding author. Fax: +48-22-6323789; e-mail: chmiel@icho.edu.pl

<sup>†</sup> Dedicated to Professor Dr. Joachim Thiem in the year of his 60th birthday.

have effected migration or rearrangement of the ethylene fragment in **2–5**, we decided to use propenyl ethers in this study. The [2+2]cycloaddition of CSI to **6**, followed by reduction of the *N*-chlorosulfonyl group with Red-Al,<sup>1–6,13</sup> afforded the  $\beta$ -lactam **10** as a single *cis*-diastereomer in 82% yield.<sup>11</sup> The trityl protecting group of **10** was then removed cleanly by treatment with sodium in liquid ammonia to give **11** in 74% yield and the hydroxy group was subsequently tosylated under standard conditions. The intramolecular alkylation of the  $\beta$ -lactam nitrogen in **12** using a two-phase system (anhydrous potassium carbonate/tetrabutylammonium bromide) in acetonitrile led<sup>1,2</sup> to formation of 5-oxacepham **16**<sup>11</sup> in 60% yield. The structure and (6*R*) configuration of **16** was confirmed by X-ray crystallography (Fig. 1).<sup>14</sup>



The cycloaddition performed on **8** and **9** afforded two corresponding *cis* azetidin-2-ones in each case: **13** and **14** in a ratio of 2:1, respectively, in 69% yield and **12** and **15** in a ratio of 3:1, respectively, in 52% yield. The **13/14** and **12/15** mixtures were separated into pure

components, which were independently subjected to cyclization to afford **16** and **17**. The structure and (6*S*) configuration of **17**<sup>11</sup> was again established by X-ray crystallography (Fig. 1).<sup>14</sup>

The results of the cycloadditions indicate an *s-trans* conformation of the olefin<sup>6</sup> in the transition state and steric control of the reaction. The bulky trityl group blocks the approach of CSI to the *re*-face, whereas substituents smaller than trityl (i.e. tosyl or mesyl) allow access of CSI to either side of the olefin.

Stereocontrolled formation of the (6*S*) configuration in cepham **23** of the same tricyclic skeleton as **16** and **17** can be achieved by a different methodology.<sup>7,15</sup> The crucial substrate for the synthesis of compound **23** was obtained from **4** by a standard reaction sequence involving protection of **4** as its *p*-methoxybenzyl ether, removal of the silyl protecting group of **18** and formation of the corresponding triflate **20**. Alkylation of the  $\beta$ -lactam nitrogen atom in **21** with **20** in the presence of tetrabutylammonium hydrogen sulfate/*n*-BuLi in THF<sup>15</sup> afforded a mixture of diastereoisomers **22**, that could be easily separated by chromatography. Subsequently, BF<sub>3</sub>-etherate-catalysed transformation of each stereoisomer of **22** afforded the same (6*S*)-cepham **23** from either compound.<sup>16</sup> The (6*S*) configuration of **23** was established by X-ray crystallography (Fig. 1).




Figure 1. X-Ray structures of cephams **16**, **17** and **23** with crystallographic numbering scheme.

Thus, it was demonstrated that the configuration at C-(6), which is crucial for biological activity of  $\beta$ -lactam antibiotics, can be controlled by selection of the strategy for cepham formation. The *trans* fused ring system provides a rigid template which could induce an alteration of geometry of the  $\beta$ -lactam nitrogen atom in isomers **16** and **17**. The crystal structures displayed in Fig. 1 show that there are some changes in geometry of the 'decalin' system between **16** and **17/23**, but irrespective of the relative configuration at C-(3), C-(4) and C-(6) the environment of the nitrogen atom is only slightly pyramidal in all cephams obtained. The distance of the nitrogen atom from the plane formed by C-(2), C-(6) and C-(8) carbon atoms amounts to only 0.250 (2), 0.260 (3) and 0.256 (2) Å, respectively.

### Acknowledgements

The authors wish to thank the State Committee for scientific Research Grant No T 09/PBZ.06.04 for support of this work.

### References

- Kałuza, Z.; Furman, B.; Patel, M.; Chmielewski, M. *Tetrahedron: Asymmetry* **1994**, *5*, 2179–2186.
- Kałuza, Z.; Furman, B.; Chmielewski, M. *Tetrahedron: Asymmetry* **1995**, *6*, 1719–1730.
- Furman, B.; Kałuza, Z.; Chmielewski, M. *J. Org. Chem.* **1997**, *62*, 3135–3139.
- Neuß, O.; Furman, B.; Kałuza, Z.; Chmielewski, M. *Heterocycles* **1997**, *45*, 265–270.
- Furman, B.; Molotov, S.; Thürmer, R.; Kałuza, Z.; Voelter, W.; Chmielewski, M. *Tetrahedron* **1997**, *53*, 5883–5890.
- Furman, B.; Krajewski, P.; Kałuza, Z.; Thürmer, R.; Voelter, W.; Williamson, M. P.; Chmielewski, M. *J. Chem. Soc., Perkin Trans. 2* **1999**, 217–224.
- Kałuza, Z.; Furman, B.; Krajewski, P.; Chmielewski, M. *Tetrahedron* **2000**, *56*, 5553–5562.
- (a) Barker, S. A.; Foster, A. B.; Haines, A. H.; Lehmann, J.; Webber, J. M.; Zweifel, G. *J. Am. Chem. Soc.* **1963**, *85*, 4161–4167; (b) Barker, R.; MacDonald, D. L. *J. Am. Chem. Soc.* **1960**, *82*, 2301–2303.
- Hartman, F. C.; Barker, R. *J. Org. Chem.* **1963**, *28*, 1004–1008.
- Marusawa, H.; Setoi, H.; Kuroda, A.; Sewada, A.; Seki, J.; Motoyama, Y.; Tanaka, H. *Bioorg. Med. Chem.* **1999**, *7*, 2635–2645.
- All new compounds were fully characterized by spectral and analytical data. Selected data of representative compounds **6**, **10**, **16**, **17** and **23** are given below:  
**6**: mp 59–61°C;  $[\alpha]_D = -3.1$  (c 0.4, CH<sub>2</sub>Cl<sub>2</sub>); IR (CHCl<sub>3</sub>) 1669 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  5.85 (dq, 1H, *J* = 1.7, 6.1 Hz, H-1'), 4.71 (q, 1H, *J* = 5.0 Hz, H-1''), 4.21 (dq, 1H, *J* = 6.1, 6.8 Hz, H-2'). HRMS (ESI) *m/z* (M+Na)<sup>+</sup> found: 453.2048, calcd for C<sub>28</sub>H<sub>30</sub>O<sub>4</sub>Na: 453.2036.  
**10**: mp 136–138°C;  $[\alpha]_D = -19.2$  (c 0.4, CH<sub>2</sub>Cl<sub>2</sub>); IR (film) 1774 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  4.84 (d, 1H, *J* = 4.5 Hz, H-4'), 4.72 (q, 1H, *J* = 5.0 Hz, H-1''), 2.88 (qdd, 1H, *J* = 2.5, 4.5, 7.5 Hz, H-3'), 1.44 (d, 3H, *J* = 5.0 Hz, CH<sub>3</sub>'), 0.85 (d, 3H, *J* = 7.5 Hz, CH<sub>3</sub>). HRMS (EI) *m/z* M<sup>+</sup> found: 473.2206, calcd for C<sub>29</sub>H<sub>31</sub>O<sub>5</sub>N: 473.2202.  
**16**: mp 59–61°C;  $[\alpha]_D = +111.5$  (c 0.6, CH<sub>2</sub>Cl<sub>2</sub>); IR (film) 1769 cm<sup>-1</sup>; <sup>1</sup>H NMR (C<sub>6</sub>D<sub>6</sub>)  $\delta$  4.54 (d, 1H, *J* = 3.3 Hz, H-6), 2.70 (qdd, 1H, *J* = 1.8, 3.3, 7.6 Hz, H-7), 1.22 (d, 3H, *J* = 5.1 Hz, CH<sub>3</sub>), 0.92 (d, 3H, *J* = 7.6 Hz, CH<sub>3</sub>). HRMS (ESI) *m/z* (M+Na)<sup>+</sup> found: 236.0891, calcd for C<sub>10</sub>H<sub>15</sub>NO<sub>4</sub>Na: 236.0893.  
**17**: mp 68–71°C;  $[\alpha]_D = -16.0$  (c 0.5, CH<sub>2</sub>Cl<sub>2</sub>); IR (film) 1769 cm<sup>-1</sup>; <sup>1</sup>H NMR (C<sub>6</sub>D<sub>6</sub>)  $\delta$  4.17 (d, 1H, *J* = 3.8 Hz, H-6), 2.76 (qdd, 1H, *J* = 1.5, 3.8, 7.5 Hz, H-7), 1.20 (d, 3H, *J* = 5.1 Hz, CH<sub>3</sub>), 1.05 (d, 1H, *J* = 7.5 Hz, CH<sub>3</sub>). HRMS (ESI) *m/z* (M+Na)<sup>+</sup> found: 236.0886, calcd for C<sub>10</sub>H<sub>15</sub>NO<sub>4</sub>Na: 236.0893.  
**23**: mp 94–96°C;  $[\alpha]_D = -71.9$  (c 0.3, CH<sub>2</sub>Cl<sub>2</sub>); IR (film) 1771 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  5.06 (d, 1H, *J* = 3.3 Hz, H-6), 2.76 (ddd, 1H, *J* = 1.7, 3.3, 15.1 Hz, H-7a), 2.81 (dd, 1H, *J* = 0.5, 15.1 Hz, H-7b), 1.33 (d, 3H, *J* = 5.1 Hz, CH<sub>3</sub>). HRMS (ESI) *m/z* (M+Na)<sup>+</sup> found: 222.0739, calcd for C<sub>9</sub>H<sub>13</sub>NO<sub>4</sub>Na: 222.0737.
- Łysek, R.; Furman, B.; Kałuza, Z.; Chmielewski, M. *Polish J. Chem.* **2000**, *74*, 51–60.
- Chmielewski, M.; Kałuza, Z.; Abramski, W.; Bełżecki, C.; Grodner, J.; Mostowicz, D.; Urbański, R. *Synlett* **1994**, 539–541.
- Crystallographic data for the structures reported in this paper have been deposited with the Cambridge Crystallographic Data Centre, Cambridge, UK, as a supplementary publication: **16**, CCDC 159585; **17**, CCDC 159584; **23**, CCDC 159586.
- (a) Kałuza, Z.; Park, S.-H. *Synlett* **1996**, 895–896; (b) Kałuza, Z.; Łysek, R. *Tetrahedron: Asymmetry* **1997**, *8*, 2553–2560.
- Kałuza, Z. *Tetrahedron Lett.* **1999**, *40*, 1025–1026.